Firstred Capital has already completed six deals from its debut fund, making commitments that are flexible in structure to Chinese companies that need its M&A expertise
Few independent Chinese managers hit the $1 billion – or RMB6.8 billion – mark with their debut renminbi-denominated fund. But Firstred Capital has done just that. It helps to have a high-profile...
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
Iluvatar CoreX, a Shanghai-based computing chip designer has raised RMB1.2 billion ($186 million) in Series C funding led by Cedarlake Capital and Centurium Capital.
China’s less-than-truckload logistics market, which sits in between express couriers and big truck operators, is ripe for consolidation. GPs have identified their favored players
US-based Platinum Equity has exited its control position in Sensis, best known as the operator of Australia’s White Pages and Yellow Pages directories, in a deal worth $200 million.